SCHEMBL3122208

SCHEMBL3122208

COc1ccc2c(N3CCC(N(C)C)C3)nc(C#N)c(-c3ccccc3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 5/20 0.47
KCNH2 Q12809 5/20 0.47
CHRM1 P11229 1/20 0.42
HRH1 P35367 1/20 0.42
CHEK2 O96017 4/20 0.41
NTSR1 P30989 1/20 0.41
HTR1D P28221 2/20 0.39
HTR3A P46098 2/20 0.39
HTR6 P50406 2/20 0.39
TMEM97 Q5BJF2 2/20 0.39
MAPK8 P45983 2/20 0.39
BTK Q06187 2/20 0.39
MRGPRX2 Q96LB1 2/20 0.39
HTR1A P08908 1/20 0.39
DRD2 P14416 1/20 0.39
HTR1B P28222 1/20 0.39
SLC6A3 Q01959 1/20 0.39
ADRA1B P35368 1/20 0.39
MAPK10 P53779 1/20 0.39
MCHR1 Q99705 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3122216 0.90 KCNH2 (0.47) KCNA5KCNH2CHRM1HRH1CHEK2
SCHEMBL1382620 0.87 KCNA5 (0.50) KCNA5KCNH2NTSR1HTR6
SCHEMBL5505607 0.87 KCNA5 (0.50) KCNA5KCNH2NTSR1HTR6
SCHEMBL1383782 0.87 KCNA5 (0.50) KCNA5KCNH2NTSR1HTR6
SCHEMBL1383656 0.85 KDM4E (0.53) KCNA5KCNH2NTSR1HTR6
SCHEMBL1385352 0.83 KCNA5 (0.53) KCNA5KCNH2
SCHEMBL1382239 0.83 KCNA5 (0.53) KCNA5KCNH2
SCHEMBL1385829 0.82 KCNA5 (0.53) KCNA5KCNH2MAPK8
SCHEMBL1384650 0.82 KCNA5 (0.53) KCNA5KCNH2MAPK8
SCHEMBL1381875 0.82 KCNA5 (0.53) KCNA5KCNH2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691879-B2 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2010-04-06 US disclosed
US-7691879-B2 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2010-04-06 US disclosed
US-7691879-B2 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2010-04-06 US disclosed
EP-1667979-A4 ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS MERCK & CO INC (US) 2007-04-18 EP disclosed
US-20060276450-A1 Isoquinoline potassium channel inhibitors MERCK SHARP & DOHME CORP. 2006-12-07 US disclosed
EP-1667979-A2 ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2006-06-14 EP disclosed
WO-2005030130-A2 ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276450-A1 Isoquinoline potassium channel inhibitors KCNQ1, KCNQ2, KCNJ2 KCNA5 15/4885KCNH2 5/4885CHRM1 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.